Physician profile
Kirk Lercher
NPI 1346401726
$1,223.03
in general payments reported to CMS, 2019-2025
14 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Brain Injury Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $165).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $337 · 2021: $152 · 2022: $14.66 · 2023: $170 · 2024: $237 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $612.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $305.27 | 2020-2022 | |
| Merz North America, INC. | $244.68 | 2019-2020 | |
| Abbvie INC. | $159.76 | 2023-2025 | |
| Merz Pharmaceuticals, LLC | $134.45 | 2023-2025 | Xeomin, Inbrija |
| Azurity Pharmaceuticals, INC. | $98.04 | 2023-2025 | Horizant, Horizant |
| Argenx US, INC. | $69.88 | 2024-2025 | Vyvgart Hytrulo |
| Ipsen Biopharmaceuticals, INC | $60.45 | 2019 | |
| Amgen INC. | $35.18 | 2025 | Repatha |
| Bioventus LLC | $29.19 | 2024 | L300 Go System |
| Coloplast Corp | $22.51 | 2023 | Speedicath |
| Axsome Therapeutics, INC. | $17.95 | 2023 | Sunosi |
| Otsuka America Pharmaceutical, INC. | $16.27 | 2023 | Nuedexta |
| Lundbeck LLC | $15.52 | 2024 | Vyepti |
| Alexion Pharmaceuticals, INC. | $13.88 | 2024 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirk Lercher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.